U.S. FDA has just cleared the IND application of bacteriophage cocktail TP-102 to initiate Phase I/IIa clinical trial. TP-102 is a cocktail of five bacteriophages that is being developed for the topical treatment of diabetic foot ulcers against Staphylococcus aureus, Pseudomonas aeruginosa and Acinetobacter baumannii. TP-102 bacteriophage therapy may be an effective and novel therapeutic approach for addressing the serious problems associated with diabetic foot infections and other chronic skin and soft tissue infections.
This innovative biological medicine is the first product of TechnoPhage’s pipeline that has reached clinical phases. The clinical trial is expected to start in the last trimester of 2020.